Handelsavisen
prelaunch
Companies ›Healthcare ›ENE.WA
EN
ENE.WA — Warsaw Stock Exchange Healthcare Facilities & Services

Centrum Medyczne Enel Med SA

$19,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
2,8 %
ROE
6,9 %
Net margin
1,5 %
Debt / equity
1,84
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Centrum Medyczne Enel Med SA operates in the healthcare facilities and services industry, providing medical services and related healthcare solutions.

Business. Centrum Medyczne Enel Med SA (ENE.WA) is a healthcare facilities and services company headquartered in Poland. The firm operates within the Healthcare Services & Equipment sector, providing medical services and related healthcare solutions. It is primarily listed on the Warsaw Stock Exchange. Specific operating segments and geographic breakdowns are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
6,9 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ENE.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ENE.WA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Centrum Medyczne Enel Med SA (ENE.WA) is a healthcare facilities and services company headquartered in Poland. The firm operates within the Healthcare Services & Equipment sector, providing medical services and related healthcare solutions. It is primarily listed on the Warsaw Stock Exchange. Specific operating segments and geographic breakdowns are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 1.84, indicating a significant reliance on debt financing. Its liquidity position is moderate, with a current ratio of 0.6, suggesting that the company may face challenges in meeting its short-term obligations. The company's return on equity is 6.94%, which is relatively low, and its return on assets is 2.02%, indicating that the company is not generating substantial returns on its asset base.

    In terms of profitability, the company's operating income is 23,809,000 PLN, and its net income is 12,892,000 PLN. The gross profit is 79,644,000 PLN, which is a significant portion of the total revenue of 854,268,000 PLN. However, the company's profitability metrics are below the industry median, suggesting that it may be underperforming compared to its peers.

    The company's revenue is primarily concentrated in a single segment, as disclosed in its financial statements. There is no significant geographic diversification, and the company's operations are primarily based in Poland. This concentration may expose the company to higher risks if there are any adverse changes in the local market.

    The company's growth trajectory is modest, with a current revenue of 854,268,000 PLN. The analyst estimate for the last actual revenue is 441,144,000 PLN, which is significantly lower than the reported revenue. This discrepancy may indicate potential issues with the accuracy of the financial reporting or the company's performance.

    The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to raise additional capital to meet its obligations. The dilution potential is low, but the company's reliance on debt financing may increase its financial risk.

    Recent events, as disclosed in the financial statements, include a significant capital expenditure of -77,596,000 PLN. This indicates that the company is investing in its operations, which may be a positive sign for future growth. However, the negative value suggests that the company is spending more on capital expenditures than it is generating in cash flow.

    Key takeaways
    • The company has a high debt-to-equity ratio, indicating a significant reliance on debt financing.
    • The company's liquidity position is moderate, with a current ratio of 0.6.
    • The company's profitability metrics are below the industry median, suggesting underperformance.
    • The company's revenue is concentrated in a single segment, increasing its exposure to market risks.
    • The company's capital expenditure is negative, indicating significant investment in operations.
    • "margin_outlook_rationale": "The company's margin outlook is uncertain due to its low profitability metrics and high debt-to-equity ratio.",

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $19,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $185.8M
    Net cashⓘ
    -$307.9M
    Current ratioⓘ
    0.6
    Debt / equityⓘ
    1.8
    ROAⓘ
    2.0%
    ROEⓘ
    6.9%
    Cash conversionⓘ
    850.0%
    CapEx / revenueⓘ
    -9.1%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin2,8 %Below median
    Net Margin1,5 %Below median
    ROE6,9 %Above median
    Capex / Rev-9,1 %Below median
    D/E1,84Bottom quartile
    Cash Conv8,50Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Centrum Medyczne Enel Med SA Market data — financials · 2026-05-27
    • Centrum Medyczne Enel Med SA Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Leadership

    • Anna Maria RozwadowskaChairman of the Supervisory Board
    • Bartosz Adam RozwadowskiMember of the Management Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ENE.WACanonical
    Warsaw Stock Exchange · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage